I am an experienced senior preclinical DMPK and DDI (Drug-Drug Interactions) scientist, manager and consultant working in Drug Development for over 30 years in Life Sciences with both Contract Research and Pharma companies.  I am based in Northamptonshire in the UK.

 

One of my focused areas in particular, is in the application of modern in vitro techniques to support crucial aspects of modern DMPK requirements, particularly Regulatory DDI assessment and other IND-enabling studies.

 

I have developed, managed and led numerous R&D departments. I have extensive experience of scientific and regulatory consultancy, development of strategic marketing, revenue building (inbound and outbound), business development and client management (Europe/International Overseas - USA/Japan) for all aspects of DMPK, DDI and ADMET.

 

I have worked on numerous successful NDAs and regularly give webinars and presentations at Scientific meetings and to clients F2F on the critical aspects of Regulatory DMPK: ADME, DDI, MIST (Metabolites In Safety Testing) and DILI (Drug Induced Liver Injury).

 

​I author the appropriate sections for BBs, CTAs, IND (2.6.4/5) and IBs.

 

My previous positions, all within DMPK, have included:

​

+ Senior Director Non-Clinical Development (ICON PLC)

+ Group Leader, Discovery DMPK (Evotec)

+ Scientific Manager, Commercial and Scientific Strategy (Covance)

+ Chief Scientist (Quotient Bioresearch/Pharmaron)

+ Head of In Vitro Metabolism (BioDynamics Research Ltd)

+ ADME and DDI Projects Manager (GW Pharmaceuticals Ltd)

+ Senior Research Scientist (GSK)

 

In these roles I have worked with many different companies on a wide variety of molecules (small, large, hybrid eg. ADC) and have been part of various IND and NDA teams.

 

In particular, I am expert in Cannabinoid(s) DMPK and their DDI assessment(s).